- New data from the Centers for Disease Control and Prevention (CDC) revealed that people of color with a COVID-19 diagnosis were much less likely to receive Paxlovid and other treatments than white patients. Between April to July 2022, Paxlovid treatment was 36 percent lower among Black patients and 30 percent lower among Hispanic patients relative to White patients. The study found disparities in other treatments — including molnupiravir, remdesivir, and bebtelovimab — but they were much less frequently prescribed than Paxlovid, which is the most commonly prescribed medication and the preferred outpatient therapeutic for eligible patients. (Report here; Articles here and here)
October 28, 2022
Inequities and SDOH